FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like How This Little Biopharma Could Beat Amgen, Teva to the Migraine Finish Line January 16, 2018 ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2017 Financial Results July 13, 2017 Janssen R&D Establishes First-Of-Its-Kind Mobile Medication And Data Management Technology Platform For Industry Use October 10, 2017
ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2017 Financial Results July 13, 2017
Janssen R&D Establishes First-Of-Its-Kind Mobile Medication And Data Management Technology Platform For Industry Use October 10, 2017
